Company ProfilePremium

Amplia Therapeutics Limited

Company Profile Analysis

Ticker: ATX.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Amplia Therapeutics Limited - Company showcase

Year Founded & Workforce

2000

Amplia Therapeutics Limited logo

Amplia Therapeutics Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Amplia Therapeutics Limited Overview

Amplia Therapeutics is a Melbourne-based, single-asset-centric oncology developer. Its lead asset is narmafotinib (AMP945), a highly selective oral inhibitor of focal adhesion kinase (FAK). FAK drives fibrotic stroma, immune suppression and drug-resistance signalling in solid tumours. Narmafotinib holds US FDA Orphan Drug and Fast Track designations in pancreatic cancer. In the single-arm Phase 1b/2a ACCENT trial it was combined with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer. The combination produced a centrally reviewed objective response rate of 35.9%, a 7.8% complete response rate, median PFS of 7.7 months and median OS of 11.1 months, each numerically above the historical MPACT chemotherapy benchmark. The strategy is to make narmafotinib a "combination backbone": a registration path in pancreatic cancer (ACCENT Mini, then a Phase 2b/3), an ovarian cancer study with ANZGOG, and a KRAS-inhibitor combination in NSCLC with Eli Lilly. The company is funded by equity and the R&D Tax Incentive. It has no revenue and is roughly six quarters from needing new capital at current burn.


Company's own description (FY2026 Annual Report, Directors' Report)

The FY2026 directors' report gives the principal activity as developing two FAK-inhibiting drug candidates, narmafotinib (AMP945) and AMP886. According to the report, both compounds have strong potency and selectivity, good pharmacokinetics and drug-like properties, preclinical efficacy, and chemistry suited to manufacturing scale-up and long-term stability. The company is pursuing them across oncology (notably pancreatic cancer) and chronic fibrotic disease. The boilerplate "About Amplia" text calls the company an Australian pharmaceutical business advancing a pipeline of FAK inhibitors for cancer and fibrosis, with a focus on fibrotic cancers such as pancreatic and ovarian cancer.

Independent characterisation

Revenue component (FY2026, AUD)Amount% of total
R&D Tax Incentive (refundable offset)4,778,23587.0%
Interest income699,09712.7%
Government grants12,0000.2%
Other income1,0000.0%
Total revenue and other income5,490,332100%
MarketSize claimed (USD)Basis
Pancreatic cancer2.5 billion2025, 7 major markets
Ovarian cancer3.9 billion2025, 7 major markets
Lung cancer32 billionglobal
Colorectal cancer19 billionglobal

Amplia is a virtual, outsourced, clinical-stage small-molecule developer. Its value chain position is in-licensed discovery-stage IP taken through clinical development, with the aim of partnering or out-licensing before Phase 3 or commercialisation. The model is capital-light:

Discovery origin: the Cancer Therapeutics CRC (CTx), Melbourne. Intellectual property is in-licensed from Cancer Research Technology Ltd (CRT, now Cancer Research Horizons) under a March 2018 licence.

Manufacturing: outsourced to a contract development and manufacturing organisation. Laurus (India) is named for API manufacture.

Clinical execution: outsourced to CROs and hospital sites in Australia, South Korea and the US, plus investigator-initiated trials sponsored by cooperative groups (ANZGOG).

Partnering: non-exclusive clinical supply collaborations with large pharma (Eli Lilly, August 2026). These are not licensing deals.

Revenue model. There is currently no product, service, subscription or licensing revenue. The mix is:

Source: FY2026 consolidated statement of profit or loss.

Prospective revenue model. The intended route to value is one or more of the following:

  • out-licensing or co-development of narmafotinib with a pharma partner, earning upfront, milestone and royalty payments;

  • acquisition of the company;

  • less likely given its scale, eventual direct commercialisation in orphan pancreatic cancer.

Royalty obligations upstream reduce net economics. Milestones are owed to CRT and the Garvan Institute, and a legacy 3.25% royalty is owed to the original MIS416 vendors on any MIS416 revenues (that legacy asset is dormant).

Customer types and end-markets (prospective). The ultimate payers would be oncology prescribers and health systems. The commercial counterparties would be large and mid-cap pharma companies. End-markets per the company's September 2026 presentation, citing Clarivate / Nature Reviews Drug Discovery 2026 and Fortune Business Insights:

Strategy

Stated strategy (paraphrased themes, FY2026 Annual Report and September 2026 deck)

  1. Advance narmafotinib to registration in first-line pancreatic cancer. A three-part FDA-aligned pathway: ACCENT Mini (daily dosing, two dose levels), then a randomised Phase 2b two-dose comparison under Project Optimus, then a pivotal Phase 3 against gemcitabine/nab-paclitaxel.

  2. Position narmafotinib as a "versatile combination agent". Pair it with less toxic chemotherapy backbones and with targeted agents, particularly KRAS inhibitors, rather than with intensive regimens. This was reinforced by the AMPLICITY halt.

  3. Expand into further fibrotic, FAK-high tumours. Ovarian cancer (PRROSE) and NSCLC (Lilly).

  4. Build CMC and regulatory readiness. Commercial-scale API, automated capsule manufacture, FDA engagement.

  5. Strengthen IP and pipeline depth. Crystal-form patent to at least 2040; new chemical entity filings to about 2046; AMP886.

  6. Broaden the investor base. OTCQB quotation, US IR, investor conferences.

  7. Business development. The Chair noted that talks with selected developers of KRAS inhibitors and other agents are under way. The Lilly agreement is the first public result.

Strategic initiatives in the last 24 months (October 2024 to October 2026)

InitiativeDateDescription / target
AMPLICITY (narmafotinib + mFOLFIRINOX)Ethics approval Jun–Jul 2025; first patient Sep 2025; halted Apr 2026US-oriented second backbone; abandoned after chemotherapy toxicity
A$27.5m capital raiseJul–Sep 2025Stated to fund clinical activities "through 2027"
OTCQB quotationOct 2025US investor access
US presence expansionOct 2025ASX headline; specifics not disclosed
Next & Bio second agreement (Korea)Dec 2025Patient-derived model screening of FAK plus KRAS-inhibitor combinations
Commercial-scale GMP manufactureJan 2026About 13 kg API
ACCENT MiniAnnounced 19 May 2026; first dosing targeted Sep 202612 patients; safety/PK by Q1 2027
PRROSE (ANZGOG)Announced 8 May 2026; protocol 15 Sep 2026About 26 patients; sites by end-2026
Board renewalJun–Jul 2026New Chair; Carter appointed
New-chemical-entity patent applicationJul 2026Potential protection to 2046
Lilly clinical collaboration4 Aug 2026Phase 1b/2b, about 60 patients, starting late 2026; Amplia-funded

Cost programmes: none announced. Resources were explicitly redeployed from AMPLICITY to ACCENT Mini.

ESG commitments: none formally announced.

Management guidance and targets

  • No financial guidance is given (normal for a pre-revenue biotech).

Operational timeline guidance (September 2026 deck): ACCENT Mini safety/PK review complete Q1 2027; FDA meeting Q2 2027; ACCENT Reg Phase 2b start 2H 2027; PRROSE recruitment before end-2026; Lilly NSCLC study start late 2026.

  • The June 2026 Appendix 4C mentions a "planned registrational submission to the FDA in Q2 2027". In context this means submitting the registrational protocol and package for the Phase 2b/3, not a marketing application.

Products & Services

Amplia has no marketed products. The catalogue below is the full disclosed development pipeline, grouped under the single segment.

Narmafotinib (AMP945): lead asset

ProgrammeIndication / lineCombinationDesignStatus (Oct 2026)
ACCENT1L metastatic pancreatic ductal adenocarcinoma (PDAC)Gemcitabine + nab-paclitaxel (Abraxane®)Phase 1b/2a, single-arm, Simon two-stage; 7 sites in Australia, 5 in Korea; 64 patients at top doseEnrolment complete; company expected completion in Q3 CY2026
AMPLICITY1L metastatic PDACModified FOLFIRINOXPhase 1b/2a under US IND; 2 Australian and 2 US sites openRecruitment halted 7 Apr 2026 after 3 chemotherapy-related DLTs in 8 patients; 5 remain on treatment
ACCENT Mini (registration stage 1)1L advanced PDACGemcitabine + Abraxane, daily narmafotinib12 patients, 2 dose cohorts, 3–4 Australian sitesFirst patient dosing targeted September 2026; safety/PK review Q1 2027
ACCENT Reg Phase 2b1L advanced PDACGemcitabine + AbraxaneRandomised two-dose comparison (FDA Project Optimus)FDA meeting planned Q2 2027; start 2H 2027
ACCENT Reg Phase 31L advanced PDACGemcitabine + Abraxane vs chemotherapy alonePivotal, controlledIn planning; partner and financing not secured
PRROSEHigh-grade serous ovarian cancer (poor responders before interval debulking surgery)Carboplatin + paclitaxelInvestigator-initiated Phase 2, ANZGOG-sponsored; about 26 patients in Australia and New Zealand (15–20 in the May 2026 release)Protocol finalised 15 Sep 2026; site activation targeted before end-2026
Lilly collaboration2L KRAS G12C-mutant NSCLCOlomorasib (Lilly, supplied in kind)Phase 1b/2b: about 20 patients in dose escalation plus about 40 in a randomised two-dose comparison; Australia and USPlanned start late 2026; Amplia sponsors and funds; non-exclusive
KRAS-inhibitor combination 2—Undisclosed KRAS inhibitorShown on the September 2026 timelineUnconfirmed / pre-announcement
EndpointACCENT (narmafotinib + gem/nab-pac)MPACT (gem/nab-pac, historical)Source
Objective response rate (confirmed)35.9% (23/64)about 23%FY2026 AR
ORR including unconfirmed responses42%—Jun-2026 Appendix 4C
Complete response rate7.8% (5/64), plus 1 pathological CRabout 0.2% (company figure)FY2026 AR; Sep-2026 deck
Disease control rate70%50%Jun-2026 Appendix 4C
Median PFS7.7 monthsabout 5.5 monthsFY2026 AR
Median OS11.1 months8.5 monthsFY2026 AR; Sep-2026 deck
Added toxicityNo significant additional burden; main narmafotinib-related adverse events were nausea, vomiting and diarrhoea—Sep-2026 deck

Description: oral, highly potent and selective small-molecule FAK (PTK2) inhibitor. It is positioned as acting on three fronts: breaking down tumour fibrosis to improve drug penetration, relieving immune suppression, and blocking survival and resistance signalling in cancer cells.

Origin and IP: discovered at the Cancer Therapeutics CRC and in-licensed from CRT. INN approved June 2023. A crystalline salt-form patent (granted US, December 2025; also allowed or granted in Australia, Japan, Europe, India, Korea, Singapore and New Zealand) extends protection to at least 2040.

Regulatory status: FDA Orphan Drug Designation (pancreatic cancer, by FY2022); FDA Fast Track (advanced pancreatic cancer, 19 Sep 2024); open US IND (January 2024).

Formulation and dosing: oral capsules. ACCENT used an intermittent schedule (dosing on 12 of each 28-day cycle, per the June 2026 Appendix 4C). The Phase 1b recommended dose was reported as 400 mg in the FY2024 AR. Daily dosing at two dose levels is now under study.

Manufacturing: about 13 kg GMP API produced in early 2026 at a CDMO (Laurus, India), described as roughly one-tenth of anticipated commercial scale. Automated capsule manufacture is in development.

Pricing model: not applicable or not disclosed. As a reference point, the company deck cites gemcitabine plus Abraxane at about US$6,500–7,500 per month and NALIRIFOX at about US$13,610 per month.

ACCENT efficacy versus the MPACT historical benchmark (centrally reviewed, data to mid-March 2026):

Analyst note: these are cross-trial comparisons of a single-arm study against a historical control. They are hypothesis-generating, not registrational. The FDA has required a controlled comparison for approval, as the CEO acknowledged in the FY2026 letter.

AMP886: second candidate

Description: multi-kinase inhibitor of FAK, VEGFR3 and FLT3.

Stage: preclinical, targeting solid tumours.

Licence status: CRT extended the IND/Phase 1 deadline to 31 Dec 2023 (FY2022 AR). Current diligence status versus the licence is not publicly disclosed.

Target customer: prospective pharma partner.

Novel FAK-inhibitor series (new chemical entities)

Description: chemically novel compounds closely related to narmafotinib. A patent application was published in July 2026, with potential protection to 2046 if granted.

Stage: discovery / preclinical.

Fibrotic disease programmes

  • Idiopathic pulmonary fibrosis (IPF) and other fibrotic disease: listed in the pipeline. A Phase 2 IPF trial was planned for 2H 2022 (FY2022 AR) but has not been initiated, and current status is not disclosed. Chronic toxicology studies to support IPF dosing were run in 2022.

Topical scar reduction / wound healing: a topical formulation of FAK inhibitors developed with CSIRO under an AusIndustry Entrepreneurs' Programme grant (May 2023). The pipeline showed it at "proof of concept developed" in FY2024. No clinical plans are disclosed.

Legacy asset

MIS416: (immunomodulator microparticle, from Innate): discontinued after the 2017 MS failure. A 3.25% royalty on any MIS416 revenues for radiation injury remains payable to the original vendors. The asset is commercially dormant.

Financial Narrative

All figures are AUD millions unless stated. They come from the audited consolidated statements in the FY2022, FY2024 and FY2026 Annual Reports; FY2023 comparatives are from the FY2024 AR and FY2025 comparatives from the FY2026 AR. Rows marked "derived" are analyst calculations from those statements. Product revenue was zero in every year.

Income statement

Margins. Gross, operating, EBITDA and net margins are n.m. because there is no product revenue. Measured against "revenue and other income", the FY2026 net loss equals -140% of that line. That ratio has no economic meaning and is shown only for completeness.

Revenue CAGR. On total revenue and other income, FY2022 to FY2026 compounds at about 29.0% a year (A$1.98m to A$5.49m). This reflects a rising R&D-incentive claim on rising R&D spend plus higher interest income on larger cash balances. It is not commercial growth.

Commentary.

Trend: R&D expense rose every year (+24% in FY2023, +24% in FY2024, +30% in FY2025, +21% in FY2026) as the company moved from a healthy-volunteer study to a multi-country Phase 2 programme, GMP scale-up and a second trial.

FY2024 inflection: the net loss fell 28% in FY2024 despite higher R&D. A catch-up of R&D-incentive income (A$4.44m against A$1.15m in FY2023) made the R&D-incentive share of R&D spend jump to 76%. This flatters the FY2024 loss and should be treated as a timing effect.

FY2026 drivers: the loss widened 17% to A$7.71m. The causes were R&D of A$9.08m (ACCENT completion, AMPLICITY start-up, CMC scale-up), administrative costs up 31% (US capital-markets presence, OTCQB, investor relations, board renewal) and patent costs up 83% (prosecution of the crystal-form and new-chemical-entity families). Interest income of A$0.70m (2.5 times FY2025) partly offset these increases, reflecting the larger post-placement cash balance.

Per-share losses: fell to -1.64c in FY2026 because weighted shares rose sharply after the July–September 2025 raisings. This is dilution, not efficiency.

Balance sheet

Commentary.

Balance-sheet troughs: FY2024 was the trough. Cash fell to A$3.39m and the company relied on a director loan (A$1.47m from Dr Peach at 10% simple interest) and an underwritten rights issue to stay funded.

Repair: the A$27.5m raise in July–September 2025 fully repaired the balance sheet, leaving A$27.85m cash and nil borrowings at 31 March 2026.

Accumulated losses: of A$152.8m mostly reflect the Innate/MIS416 era. Losses under the Amplia strategy (FY2019 to FY2026) total roughly A$34m.

Intangible: the A$7.94m licence intangible is carried at its 2018 deemed acquisition cost and is not amortised (not yet ready for use). It is tested for impairment annually as a key audit matter.

Cash flow

Commentary. Operating cash burn roughly doubled from A$4.4m (FY2022) to A$8.7m (FY2026). Capital spending is negligible because the model is virtual. Gross equity raised over five years totals about A$61.5m, against roughly A$30.4m of cumulative operating outflow.

The Q1 FY2027 (June 2026 quarter) Appendix 4C shows A$3.87m net operating outflow (R&D A$2.95m, staff A$0.46m, administration A$0.68m, interest received A$0.22m) and closing cash of A$23.98m. The company estimates 6.2 quarters of funding.

There is a data conflict here. The same Appendix 4C text describes the March 2026 quarter as A$3.5m of operating "inflows", whereas InvestSMART's summary of the March 4C reports A$3.5m of net outflows. The movement in cash from A$31.5m (December 2025) to A$27.9m (March 2026) supports an outflow, so the "inflows" wording is likely a drafting error.

An FY2026 R&D-incentive receivable of A$4.78m should be collected in roughly Q2–Q3 FY2027, following the pattern of October 2025, which would extend runway.

Ratios

The following ratios are n.m.: ROIC (negative operating returns on a non-earning intangible base), net debt / EBITDA (net cash and negative EBITDA), interest coverage (negative EBIT), and the cash conversion cycle (no inventory or trade receivables).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionFunctionStatus

Amplia Therapeutics Limited

Australia

Listed parent; R&D sponsor

Active

ACN 612 556 948 Pty Ltd (formerly Amplia Therapeutics Pty Ltd)

Australia

Licence-holding company for AMP945/AMP886

100% owned

Amplia Therapeutics (UK) Limited

United Kingdom

Dormant R&D vehicle

Deregistered 15 Mar 2022

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Revenue and other income, single segment (AUD Mn)

4.604.065.49

Loss before income tax, single segment (AUD Mn)

-4.50-6.57-7.71

YoY change in revenue and other income (%)

257.3-11.735.2

Share of group revenue (%)

100100100

Income Statement

MetricFY2022FY2023FY2024FY2025FY2026

Product revenue (AUD Mn)

00000

R&D tax incentive income (AUD Mn)

1.981.154.443.774.78

Interest income (AUD Mn)

0.000.100.150.280.70

Government grants and other (AUD Mn)

0.000.040.020.010.01

Total revenue and other income (AUD Mn)

1.981.294.604.065.49

Gross profit (AUD Mn)

00000

R&D expense (AUD Mn)

3.774.695.807.539.08

Patent and associated expense (AUD Mn)

0.150.310.440.210.39

Administrative and general expense (AUD Mn)

1.642.202.602.673.49

Share-based compensation (AUD Mn)

0.060.210.090.080.13

Depreciation and amortisation (AUD Mn)

0.000.070.090.090.09

Total operating expenses (AUD Mn)

5.637.489.0210.5813.18

Operating deficit before financing (AUD Mn)

-3.64-6.19-4.42-6.52-7.69

EBITDA excl. interest income, derived (AUD Mn)

-3.64-6.21-4.48-6.71-8.30

Interest expense (AUD Mn)

0.000.050.080.060.02

Pre-tax loss (AUD Mn)

-3.64-6.24-4.50-6.57-7.71

Income tax (AUD Mn)

00000

Net loss (AUD Mn)

-3.64-6.24-4.50-6.57-7.71

EPS basic, AUD cents

-2.50-3.22-2.32-2.14-1.64

EPS diluted, AUD cents

-2.50-3.22-2.32-2.14-1.64

Dividends per share, AUD cents

00000

R&D expense as % of total opex, derived

67.062.764.371.268.9

R&D tax incentive as % of R&D expense, derived

52.624.576.450.152.6

Balance Sheet and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD Mn)

14.619.263.3910.8627.85

R&D tax incentive receivable (AUD Mn)

1.841.153.183.774.78

Total current assets (AUD Mn)

16.5310.516.7514.9333.04

Intangibles: AMP945/AMP886 licence (AUD Mn)

7.947.947.947.947.94

Goodwill (AUD Mn)

00000

Total assets (AUD Mn)

24.4818.6814.8522.9441.44

Short-term borrowings (AUD Mn)

0.002.111.490.000.00

Long-term borrowings (AUD Mn)

2.100.000.000.000.00

Lease liabilities, current + non-current (AUD Mn)

0.000.170.090.010.34

Total debt incl. leases, derived (AUD Mn)

2.102.281.590.010.34

Net debt (negative = net cash), derived (AUD Mn)

-12.51-6.98-1.80-10.85-27.51

Total current liabilities (AUD Mn)

0.532.753.401.891.67

Total liabilities (AUD Mn)

2.642.853.431.911.97

Total equity (AUD Mn)

21.8515.8411.4221.0239.47

Working capital, derived (AUD Mn)

16.007.763.3513.0431.37

Issued capital (AUD Mn)

151.51151.53151.53167.39193.43

Accumulated losses (AUD Mn)

-128.62-134.72-139.01-145.54-152.83

Shares on issue at year end (millions)

193.85194.01194.01387.95513.07

NTA per share, AUD cents

7.24.11.83.46.1

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

R&D tax incentive cash received (AUD Mn)

1.141.842.413.183.77

Payments to suppliers (AUD Mn)

-4.59-6.06-6.18-9.10-11.58

Payments to employees (AUD Mn)

-0.95-1.20-1.53-1.22-1.61

Operating cash flow (AUD Mn)

-4.40-5.29-5.13-6.89-8.73

Capex: property, plant and equipment (AUD Mn)

-0.01-0.02-0.00-0.00-0.03

Free cash flow, derived (AUD Mn)

-4.42-5.31-5.13-6.89-8.77

Gross equity proceeds incl. options (AUD Mn)

16.270.020.0017.2827.88

Capital-raising costs (AUD Mn)

-1.180.000.00-1.33-1.86

Borrowings drawn (AUD Mn)

2.100.001.470.000.00

Borrowings repaid (AUD Mn)

0.000.00-2.10-1.470.00

Net financing cash flow (AUD Mn)

17.19-0.08-0.7714.3225.94

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on average equity, derived (%)

-22.6-33.1-33.0-40.5-25.5

ROA on average assets, derived (%)

-20.6-28.9-26.9-34.8-23.9

Current ratio, derived (x)

31.23.82.07.919.8

Debt to equity incl. leases, derived (x)

0.100.140.140.000.01

Asset turnover on revenue and other income, derived (x)

0.110.060.270.210.17

Cash runway at FY-end operating burn, derived (years)

3.31.70.71.63.2

Revenue by Region and Region Margins & Growth (%)

RegionFY2024FY2025FY2026

Australia: revenue and other income (AUD Mn)

4.604.065.49

Americas: revenue (AUD Mn)

000

EMEA: revenue (AUD Mn)

000

APAC ex-Australia: revenue (AUD Mn)

000

Australia YoY growth (%)

257.3-11.735.2

Per-Share Data and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 31 March (AUD cents)

14.58.57.07.023.5

Shares on issue at 31 March (millions)

193.85194.01194.01387.95513.07

Market cap at 31 March, derived (AUD Mn)

28.116.513.627.2120.6

Net cash at 31 March, derived (AUD Mn)

12.57.01.810.827.5

Enterprise value at 31 March, derived (AUD Mn)

15.69.511.816.493.1

Valuation Multiples

MultipleAmpliaComment

EV/Sales

About 6.9x on "revenue and other income"

n.m. economically (R&D-incentive income)

P/B

About 1.56x (A$61.6m / A$39.47m equity at 31 Mar 2026)

Book is mainly cash plus the A$7.9m licence

Market cap / cash

About 2.6x (vs A$24.0m at 30 Jun 2026)

The market assigns about A$38m EV to the pipeline

Raising by Period

PeriodRaising

FY2022

A$16.27m

FY2024 (closed May 2024)

A$4.27m entitlement offer at about 5.5c

FY2026

A$27.88m (placement at 23c, SPP at 18c, options)

Analyst Conclusions

Management guidance (operational; no financial guidance)

ItemExpected timing
ACCENT Mini first dosingSeptember 2026
ACCENT Mini safety/PK reviewQ1 2027
FDA meeting on the registrational Phase 2b designQ2 2027
Registrational Phase 2b start2H 2027
PRROSE site activation and recruitmentBefore end-2026
Lilly NSCLC Phase 1b/2b startLate 2026
Mature AMPLICITY data on the 5 remaining patients"In due course"
Second KRAS-inhibitor combinationOn the timeline; undisclosed

Consensus growth expectations

No meaningful revenue or earnings consensus exists. The single published broker target (A$0.42, Bell Potter, pre-April 2026) implies a large perceived discount to risk-adjusted pipeline value, but it predates the AMPLICITY halt.

Bull case

  1. Clinically differentiated signal. A 7.8% CR rate and more than two months of mOS/mPFS improvement over MPACT, with no added toxicity, is rare in 1L metastatic PDAC. Daily dosing (ACCENT Mini) could deepen the effect.

  2. Optionality in the KRAS era. Narmafotinib's resistance-blocking and stroma-remodelling mechanism suits combination with RAS inhibitors, a class with 80+ clinical assets and big-pharma sponsors. Lilly's in-kind collaboration is early validation and could lead to a licensing or M&A event.

  3. Asymmetric valuation. An EV of about A$38m (September 2026) for a Fast Track / Orphan asset with FDA-aligned dose optimisation, IP to 2040+, GMP scale-up done and three trials starting looks inexpensive if any study reads out positively.

Bear case

  1. Evidence quality. Single-arm ACCENT data against historical controls often overstate benefit, and the 2.6-month mOS improvement may shrink or vanish in a randomised trial.

  2. Shrinking addressable backbone. AMPLICITY showed narmafotinib cannot readily be escalated on mFOLFIRINOX (the dominant US/EU fit-patient regimen), and RAS inhibitors may push chemotherapy-centric 1L regimens aside before a Phase 3 could read out around 2029 or later.

  3. Funding and dilution. At about A$15.5m annualised burn (Q1 FY2027 run-rate) against A$24m cash plus about A$4.8m R&D refund, a raise is likely in CY2027, possibly at depressed prices. A Phase 3 is not fundable on a standalone basis.

Key catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorableWhy it matters
Late Oct 2026Sep-2026 quarter Appendix 4CBurn rate; confirmation of ACCENT Mini dosing; FY2026 R&D refund timing
Q4 2026FY2026 R&D Tax Incentive refund (about A$4.8m)Runway extension
Q4 2026PRROSE ethics approval and first patientSecond indication
Late 2026Lilly NSCLC study first patientKRAS thesis execution
26 Nov 2026Half-year report H1 FY2027Financials; going-concern language
H2 2026 / 2027Final ACCENT dataset (trial completion) and any publicationDurability and OS maturity
Q1 2027ACCENT Mini safety/PK readoutDaily-dose tolerability; whether the dose-comparison design holds
Q2 2027FDA meeting on the registrational Phase 2bRegulatory path clarity
2,027Capital raise and/or partnering announcementFunding of the Phase 2b/3
OngoingSecond KRAS-inhibitor collaboration; options overhang (A$0.17, October 2027 expiry)BD momentum; dilution

Analyst verdict

Amplia Therapeutics is now a credible, if still speculative, single-asset oncology developer. Narmafotinib has delivered one of the more interesting signals in first-line metastatic pancreatic cancer in recent years. A centrally reviewed 35.9% ORR, a 7.8% complete-response rate and an 11.1-month median OS were achieved with an intermittent schedule and no meaningful added toxicity. The FDA has engaged constructively (Orphan, Fast Track, Type D alignment). Manufacturing is ready for later-stage trials. The Lilly collaboration, although economically thin, gives third-party validation of the KRAS-combination thesis that will probably decide narmafotinib's long-term relevance.

The case is held back by three facts. First, every efficacy comparison so far is against a historical benchmark. Second, the April 2026 AMPLICITY halt removed the FOLFIRINOX backbone and with it much of the near-term US/EU commercial logic. Third, the balance sheet (A$24.0m, about six quarters of runway at the June 2026 burn) can fund dose optimisation and proof-of-concept studies but not a pivotal trial. The market's verdict is visible in the price: from about A$0.265 after the March 2026 data, the stock fell to about A$0.12 by mid-September, valuing the pipeline at roughly A$38m of enterprise value.

On balance, we see Amplia as a high-risk, catalyst-driven holding whose value depends on two things. One is converting the ACCENT signal into a partnered, randomised Phase 2b. The other is producing clinical evidence that narmafotinib improves KRAS-inhibitor outcomes. If the 2027 milestones arrive on time (ACCENT Mini safety, the FDA meeting, early Lilly-combination data), today's valuation is likely to prove too low. If a non-dilutive or partner-funded route to Phase 3 does not emerge, dilution will continue to cap returns. Position sizing should reflect binary clinical and financing risk. Rating framework: Speculative / High Risk; monitor the Q4 CY2026 to Q2 CY2027 catalysts.


Data-integrity notes

  • All financial figures are from audited annual reports (FY2022, FY2024 and FY2026, including comparatives) unless marked "derived" (analyst calculation) or attributed to secondary sources.

  • Conflicts noted:

    • Platinum's stake is quoted at 9.31% in its notice versus about 8.8% on the current share count.

    • The June 2026 Appendix 4C describes the March 2026 quarter as operating "inflows", inconsistent with the cash movement and the March 4C summary.

    • PRROSE enrolment is about 26 in the Sept 2026 release versus 15–20 in the May 2026 release.

    • A secondary article claiming a 76% share-price surge in late May 2026 is inconsistent with exchange price data (about A$0.13–0.15 in late May 2026) and has been disregarded.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundEducationAge

Jane Bell AM

Independent NED; Chair since 30 Jun 2026; Chair of Audit & Risk Committee (pre-transition)

12 Apr 2021

Banking and finance lawyer; NED since 2002 on 17 boards; Deputy Chair of Monash Health; director of Mesoblast (ASX: MSB / Nasdaq: MESO); former Chair of Royal Melbourne Hospital and BioMedVic; AM 2023

BEc (Monash), LLB (Melbourne), LLM (King's College London), FAICD

—

Dr Warwick Tong

Non-Executive Director (Chair 25 May 2018 to 30 Jun 2026)

4 May 2018

Physician; Glaxo, GlaxoWellcome, GSK, Surface Logix; CEO of the Cancer Therapeutics CRC 2011 to April 2018 (originator of Amplia's assets); director of Aculeus, Clear Scientific and Pacalis

MB ChB (Auckland), MPP (Victoria University of Wellington), GAICD

—

Dr Robert Peach

Independent NED; Chair of Remuneration & Nomination Committee

2 Sep 2015

Co-founder and CSO of Receptos (acquired by Celgene for US$7.8bn, 2015); Biogen Idec, IDEC, BMS; director of Rekover Therapeutics

PhD (Otago; also Canterbury)

70 (MarketScreener)

Brett Carter

Non-Executive Director

Early July 2026

25+ years in oncology development and business development; 8 years in GSK global corporate transactions; former CEO of Cancer Therapeutics CRC

——

Dr Christopher Burns

CEO and Managing Director

NED 4 May 2018; CEO/MD 5 Dec 2022

Medicinal chemist; Pfizer UK; Cytopia Research Director (co-discovery of momelotinib, FDA-approved 2023); WEHI Laboratory Head; Certa, MycRx; inventor on 30+ patents; co-recipient of the 2024 Prime Minister's Prize for Innovation

BSc (Hons), PhD (Melbourne), FRACI, FRSC, FAHMS, GAICD

—

“—” = not publicly disclosed.

Executive Leadership Team

NameTitleSincePrior roles

Dr Christopher Burns

CEO and MD

5 Dec 2022

See above

Hamish George

CFO

25 Feb 2026 (also CFO from 1 Oct 2021 to 2023 via Bio101)

Bio101 Financial Advisory; BCom MA CA

Dr Rhiannon Jones

COO

Not disclosed (in role by FY2024)

Cancer Therapeutics CRC; PhD GAICD

Dr Jason Lickliter

Chief Medical Officer

12 May 2025 (clinical adviser since 2021)

Medical oncologist and clinical triallist (Nucleus Network per deck); MBBS FRACP

Jonathan Barlow

Head of Business Development

—

Telix Pharmaceuticals; LLB BSc GDipBA GAICD

Andrew J. Cooke

Company Secretary

11 Oct 2013

Lawyer, corporate finance and governance; LLB (Sydney)

“—” = not publicly disclosed.

Directors' Remuneration

PersonCash salary/feesCash bonusSuperannuationShare-based (options)Total FY2026Total FY2025

Warwick Tong (Chair)

70,0000027,85697,85670,000

Robert Peach

50,0000019,89769,89750,000

Jane Bell

44,64305,35719,89769,89750,000

Christopher Burns (CEO/MD)

320,017029,98327,481377,481466,222

Total KMP

484,660035,34095,131615,131636,222

Board & Management Changes

DateChangeContext

12 May 2025

Lickliter appointed CMO

Ahead of the registrational programme

25 Feb 2026

George replaces Luscombe as CFO

Not explained beyond the appointment

30 Jun 2026

Bell succeeds Tong as Chair

Board renewal and succession plan; Tong stays as NED

Jul 2026

Carter joins board

Adds global business-development and transactions expertise ahead of partnering

Major Shareholders

HolderShares% of issued capitalDate / source

Platinum Investment Management Ltd

45,313,932

9.31% as notified (about 8.8% of the current 513.3m shares)

—

Pengana Capital Group Ltd and subsidiaries

27,544,9195.37%

22 Jun 2026 (FilingReader)

Acorn Capital Ltd

—

Substantial (≥5%) per Sep-2026 deck

Company deck

Blueflag Holdings Pty Ltd (Blueflag Trust)

—

Substantial (≥5%) per Sep-2026 deck

Company deck

Directors' Shareholdings

DirectorSharesOptions (vested)

Peach

6,131,1641,055,808

Burns

4,155,5743,207,869

Tong

3,864,073858,565

Bell

3,661,751762,329

Total

17,812,562 (about 3.5% of shares)

—

Competitive Landscape

Key Competitors

#CompanyRelevant asset(s)Overlap with AmpliaStatus (as reported)
1

Verastem Oncology (US)

Defactinib (FAK) + avutometinib (RAF/MEK)

Closest FAK comparator; validates the class

FDA accelerated approval 2025 in KRAS-mutated recurrent low-grade serous ovarian cancer (Amplia FY2026 AR / Sep-2026 deck)

2

InxMed (China)

Ifebemtinib (FAK)

FAK plus KRAS combinations

Early clinical data published 2026 (Lancet Respiratory Medicine, per Amplia deck)

3

Revolution Medicines (US)

Daraxonrasib (RAS(ON) multi-selective)

Reshaping PDAC treatment; potential combination partner or substitute for chemotherapy

Amplia's September 2026 deck reports US approval in second-line advanced PDAC in August 2026

4

Eli Lilly (US)

Olomorasib (KRAS G12C) plus G12D and pan-KRAS programmes

Partner, but also an independent PDAC/NSCLC developer

Two global Phase 3 trials in NSCLC; FDA Breakthrough Therapy for KRAS G12C PDAC (secondary report)

5

Amgen

Sotorasib (KRAS G12C)

Standard of care in KRAS G12C NSCLC

Approved

6

Bristol Myers Squibb (incl. Mirati)

Adagrasib (KRAS G12C); Abraxane (backbone)

Competitor and backbone owner

Approved

7

Ipsen

Onivyde (NALIRIFOX)

Competing 1L PDAC backbone (US-approved), described as less toxic than FOLFIRINOX

Approved (US)

8

Boehringer Ingelheim, Roche, Pfizer, J&J, Bayer, Astellas, Chugai, Erasca, BridgeBio and others

KRAS/RAS inhibitors (80+ in development per Amplia)

Competition for combination slots; also potential partners

Phase 1 to 3

9

Generic gemcitabine; FOLFIRINOX components

Chemotherapy

The backbone narmafotinib must improve on

Generic

10

Other ASX small-cap oncology developers (e.g. Race Oncology, Kazia Therapeutics, Prescient Therapeutics)

Varied

Compete for the same ASX biotech capital

Clinical

Peer Comparison FY2026

AttributeAmpliaVerastem (FAK peer)Revolution Medicines (RAS peer)Lilly (partner / competitor)

Lead modality

Selective oral FAK inhibitor

FAK inhibitor + RAF/MEK

RAS(ON) inhibitor

KRAS G12C inhibitor

Most advanced stage

Phase 1b/2a complete; registration path starting

Approved (LGSOC, 2025)

Approved per Amplia deck (2L PDAC, Aug 2026)

Phase 3 (olomorasib)

Revenue

0———

Latest cash

A$24.0m (30 Jun 2026)

———

R&D intensity

About 69% of opex

———

Recent Developments

--

Company Snapshot

2000

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Response depth: 5 confirmed CRs out of 64 (7.8%) plus 1 pathological CR, against about 0.2% CR for chemotherapy alone (FY2026 AR; Sep-2026 deck).
  • Efficacy across all endpoints versus MPACT: ORR 35.9% vs about 23%; mPFS 7.7 vs 5.5 months; mOS 11.1 vs 8.5 months; DCR 70% vs 50% (FY2026 AR; Jun-2026 4C).
  • Tolerability: no significant additional toxicity across 64 patients, despite intermittent dosing only, leaving room for daily dosing (Jun-2026 4C).
  • Regulatory designations and alignment: Orphan Drug (FY2022), Fast Track (19 Sep 2024), positive Type D (November 2025) supporting a two-dose Phase 2b.
  • Balance sheet: A$24.0m cash, nil debt, 6.2 quarters of runway (Jun-2026 4C), plus an FY2026 R&D-incentive receivable of A$4.78m.
  • CMC readiness: about 13 kg GMP API, roughly one-tenth of commercial scale (FY2026 AR).
  • Management pedigree: the CEO co-discovered momelotinib (FDA-approved 2023); director Peach co-founded Receptos (sold for US$7.8bn).

Weaknesses

  • Single-arm evidence: ACCENT has no control arm; all comparisons are to historical MPACT data (FY2024 AR trial-design section).
  • Single-asset concentration: AMP886 has not entered the clinic, despite a CRT deadline of 31 Dec 2023 (FY2022 AR).
  • No revenue: about 87% of FY2026 income is the R&D Tax Incentive (FY2026 P&L).
  • Rising burn: operating outflow up 27% to A$8.73m in FY2026, and A$3.87m in Q1 FY2027 alone, an annualised rate of about A$15.5m.
  • Failed US-oriented trial: AMPLICITY was halted after 3 DLTs out of 8 patients (7 Apr 2026).
  • Small, thin organisation: KMP disclosure covers only four directors, and payments to employees were A$1.61m in FY2026, implying a small staff.
  • Shareholder dilution history: shares rose from 193.9m (FY2022) to 513.1m (FY2026), 2.6 times, plus a 102.3m option overhang.

Opportunities

  • KRAS-combination demand: 80+ KRAS drugs are in development (Sep-2026 deck); the Lilly CTCSA provides the first clinical vehicle.
  • NSCLC entry: a market of about US$31bn growing to over US$60bn by 2033 (Lilly release).
  • Ovarian cancer: a US$3.9bn 7MM market; PRROSE is low-cost (ANZGOG-sponsored).
  • Daily dosing upside: ACCENT used 12 of 28 days, and continuous dosing may deepen responses (Jun-2026 4C).
  • Partnering or M&A: Board renewal (Carter's GSK transactions background) and talks with KRAS developers are disclosed (FY2026 Chair letter).
  • Regulatory acceleration: Fast Track enables rolling review and possible accelerated approval or priority review (ASX, 19 Sep 2024).
  • Additional R&D-incentive cash: A$4.78m receivable at 31 Mar 2026.

Threats

  • Standard-of-care disruption in PDAC: RAS inhibitors (daraxonrasib, reported approved in 2L PDAC in August 2026 per the company deck) may reduce reliance on chemotherapy over time.
  • Phase 3 funding gap: current cash covers ACCENT Mini, PRROSE support and the Lilly study, not a pivotal trial (analyst assessment based on the 6.2-quarter runway).
  • Competing FAK agents: Verastem (approved) and InxMed (clinical).
  • Equity-market dependence: the company's own risk factor (q) flags additional capital needs and dilution.
  • R&D incentive policy risk: a change to the scheme would remove about 50% of R&D cost recovery (FY2026 risk factor (h)).
  • Going-concern sensitivity: MarketScreener reported an auditor going-concern flag on 29 May 2026, while the Appendix 4E states an unmodified opinion. A material-uncertainty emphasis may exist.
  • Share-price volatility: ATX fell about 21% on 7 Apr 2026; the 2026 YTD range is A$0.10–0.275.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025US clinical trial activities for narmafotinib under wayAMPLICITY start-up
Apr 2025ACCENT interim data at AACR 2025Visibility
12 May 2025Dr Jason Lickliter appointed CMOClinical leadership
May 2025ACCENT reaches the efficacy threshold (15 confirmed PRs), described as superiority over chemotherapy aloneSimon two-stage success
30 May 2025FY2025 Annual Report: loss A$6.57mDisclosure
Jun 2025First pathological complete response, then second CR, in ACCENTDepth-of-response signal
Jun 2025US IRB (ethics) approval for AMPLICITYRegulatory
Jul 2025Additional PRs reported in ACCENTData accrual
Jul 2025A$25m placement at A$0.23 plus A$2.5m SPP launchedBalance-sheet repair
Jul 2025Australian ethics clearance for AMPLICITYRegulatory
6 Aug 2025Positive ACCENT topline data releasedCatalyst
Aug 2025SPP raises A$2.65m at A$0.18; Australian AMPLICITY sites openFunding / operations
27 Aug 20252025 AGM: all resolutions carriedGovernance
Sep 2025First patient dosed in AMPLICITY; narmafotinib adopted as US nonproprietary name; US patent allowanceMultiple
Oct 2025Additional ACCENT responses; plan to significantly expand US presence; R&D rebate A$3.77m; OTCQB trading beginsMultiple
Nov 2025Positive FDA Type D response (two-dose Phase 2b design)Regulatory de-risking
Dec 2025US crystal-form patent granted; further confirmed response; second Next & Bio agreementIP / BD
9 Jan 2026ACCENT data at ASCO GI 2026Visibility
Jan 2026Large-scale narmafotinib manufacture complete (about 13 kg API)CMC readiness
30 Jan 2026Q3 FY2026 Appendix 4C: cash A$31.5mFunding
Feb 2026US sites open for AMPLICITY; Emergence 2026 presentation (18 Feb)Operations
25 Feb 2026Hamish George appointed CFOLeadership
Mar 2026Data on narmafotinib benefit in KRAS-mutated cancer modelsPreclinical / BD
23 Mar 2026Mature ACCENT data: ORR 35.9%, CR 7.8%, mOS 11.1 months; share price later rises to about A$0.265–0.275Key catalyst
7 Apr 2026AMPLICITY recruitment halted (3 chemotherapy-related DLTs out of 8 patients; 4 of 8 stable disease at the first scan, 1 later PR); shares fall about 21% on the day (closed A$0.15 vs A$0.19 open)Major setback to the US/FOLFIRINOX strategy
8 Apr 2026MD responds to investor questions on AMPLICITYDisclosure
Apr 2026Oral presentation of mature ACCENT data at AACR 2026Visibility
28 Apr 2026Q4 FY2026 Appendix 4C: cash A$27.9mFunding
8 May 2026PRROSE ovarian trial announced with ANZGOGIndication expansion
12 May 2026240,385 shares issued on exercise of employee optionsCapital
19 May 2026First stage of registration-enabling trial (ACCENT Mini) launchedRegistration path
29 May 2026FY2026 Annual Report and Corporate Governance StatementDisclosure
22 Jun 2026Pengana Capital becomes substantial holder (5.37%)Register quality
6 Jul 2026Board leadership change (Bell Chair from 30 June)Governance
Jul 2026Brett Carter appointed NED; new FAK patent application published (9 Jul)Governance / IP
13 Jul 2026Shareholder webinarIR
27 Jul 2026Notice of AGM (includes option grants to directors)Governance
29 Jul 2026Q1 FY2027 Appendix 4C: cash A$24.0m; 6.2 quarters of fundingFunding
4 Aug 2026Lilly CTCSA (narmafotinib plus olomorasib, KRAS G12C NSCLC)BD validation
6 Aug 2026Bioshares Biotech Summit presentationIR
28 Aug 2026AGM; CEO presentation; results of meeting lodgedGovernance
9 Sep 2026Unquoted employee options issued (Appendix 3G)Capital
15 Sep 2026PRROSE protocol finalised; ethics submissions to followExecution
16 Sep 2026E&P Healthcare Conference presentation: share price A$0.12, market cap A$61.6mIR
Sep 2026ACCENT Mini first patient dosing targeted (company timeline; a formal ASX dosing confirmation was not located)Execution

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Total revenue and other income rose from AUD 2 Mn in FY2022 to AUD 5.5 Mn in FY2026.
Amplia Therapeutics Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue and other income21.34.64.15.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Amplia Therapeutics FY2026 Annual Report and Appendix 4E (29 May 2026), via financialfilings.com and InvestSMART
  2. Amplia FY2024 Annual Report (ASX, 30 May 2024) (announcements.asx.com.au)
  3. Amplia FY2022 Annual Report (ASX, 30 May 2022) (announcements.asx.com.au)
  4. Amplia FY2021 and FY2020 Appendix 4E (asx.com.au)
  5. Amplia FY2019 Financial Report and H1 FY2019 Appendix 4D (ampliatx.com)
  6. Appendix 4C, quarter ended 30 June 2026 (otcmarkets.com)
  7. Appendix 4C, quarter ended 31 December 2025 (BioSpace / Webull)
  8. ASX releases: AMPLICITY halt (7 Apr 2026); Lilly CTCSA (4 Aug 2026); PRROSE protocol (15 Sep 2026); E&P Healthcare presentation (16 Sep 2026); Board leadership changes (6 Jul 2026, GlobeNewswire); New FAK patent application (9 Jul 2026, BioSpace); ACCENT Mini launch (19 May 2026, Cancer Research Horizons); Fast Track (19 Sep 2024)
  9. InvestSMART announcement summaries and price history; MarketScreener; Motley Fool AU / Webull; Biotech Dispatch; SmallCaps; Stockhead (Tim Boreham, 2018); FilingReader (Pengana substantial holding); OncLive / CancerNetwork; Wikipedia (Innate Immunotherapeutics; MIS416)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.